Sygnature Discovery appoints new Head of In Vivo Pharmacology 

CRO Sygnature Discovery has announced the appointment of Susanne Back as Head of In Vivo Pharmacology. 

Back has 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River. She will lead one of Sygnature’s in vivo pharmacology teams, delivering the company’s in vivo strategies that it says will support informed decision-making across drug discovery programmes. 

 Back will be responsible for the scientific and operational leadership of the team, including resource planning, workflow optimisation, and the continued development of innovative and competitive in vivo capabilities. 

“I was particularly attracted to Sygnature because of its world-leading integrated drug discovery expertise and the calibre of its scientific community,” Back said. 

 “The co-located, multidisciplinary environment creates a truly collaborative setting where complex discovery challenges can be addressed efficiently. I am looking forward to working closely with colleagues and clients to ensure we continue to deliver translational in vivo data that accelerates drug discovery programmes.” 

The appointment follows Sygnature’s recent strategic brand launch, aiming to reinforce its position as a global drug discovery partner. 

The post Sygnature Discovery appoints new Head of In Vivo Pharmacology  appeared first on Drug Discovery World (DDW).